Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Leniolisib per disregolazione immunitaria in CVID

15 settembre 2026 aggiornato da: Pharming Technologies B.V.

Uno studio per valutare la sicurezza e la tollerabilità ed esplorare l'efficacia di Leniolisib per la disregolazione immunitaria nell'immunodeficienza variabile comune (CVID)

In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.

Panoramica dello studio

Stato

Completato

Intervento / Trattamento

Descrizione dettagliata

The study includes administration of increasing dose levels of leniolisib in approximately 20 CVID patients presenting with clinical manifestations of immune dysregulation at study entry. Enrollment will include both patients without and those with genetic drivers identified for their CVID.

All subjects participating will receive leniolisib film-coated tablets (FCTs) with a planned dose regimen consisting of a starting dose of 10 mg twice daily (BID) for 4 weeks, followed by a dose escalation to 30 mg BID for 4 weeks, and then 70 mg BID for an additional 16 weeks. Dose adjustments are allowed during treatment if deemed clinically necessary.

Subjects not continuing leniolisib treatment outside the current protocol will be followed up, with the EoS visit planned to occur approximately 28 days after last dose of leniolisib.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

27

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Leeds, Regno Unito
        • Leeds Teaching Hospital NHS Trust
      • Valencia, Spagna
        • IIS La Fe
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Children's Hospital Colorado
    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • National Institute of Health
    • Massachusetts
      • Burlington, Massachusetts, Stati Uniti, 01805
        • Lahey Hospital & Medical Center
    • New York
      • New York, New York, Stati Uniti, 10029
        • Mount Sinai Hospital
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 75 anni (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Subject is 12 to 75 years of age (inclusive).

    a. Specifically at sites located in the United Kingdom subjects must be 18 to 75 years of age (inclusive)

  2. Subject must have a minimum body weight of 45 kg

  3. Subject has a clinical diagnosis of CVID supported by all of the following (a thru c):

    1. A low IgG level compared to age-adjusted reference range [OR if this cannot be documented, subject must have one of the following: i) absent isohemagglutinins and/or poor response to vaccines; or ii) Low class-switched memory B cells less than 2%]
    2. Low IgA and/or IgM compared to age-adjusted reference range
    3. No identified secondary causes of hypogammaglobulinemia
  4. Inborn Errors of Immunity/ PID Panel testing:

    1. Lacks an identified pathogenic/likely pathogenic genetic driver for their CVID primary immunodeficiency OR
    2. Subject has an identified pathogenic/likely pathogenic genetic driver(s) for their CVID limited to the following genes: TNFRSF13B (TACI), TNFRSF13C (BAFFR), CD19, CD20, CD81, CR2 (CD21), LRBA, CTLA4, NFKB1, NFKB2, IKZF1 (excluding variants associated with combined immune deficiency), CARD11 (gain of function), SH3KBP1, SEC61A1 IRF2BP2, CTNNBL1, TWEAK or PTEN.
  5. Subject has lymphoproliferation, as evidenced by CT imaging: splenomegaly with craniocaudal spleen measurement >10 cm and/or lymphadenopathy with at least 1 measurable index lymph node (long axis >1.5 cm) as per Cheson methodology.

  6. Subject has at least ONE of the following CVID clinical manifestations of immune dysregulation:

    1. Clinical symptoms related to splenomegaly or lymphadenopathy which interfere with activities of daily living or are associated with chronic pain, dyspnea, functional impairment, or limitations in usual activities
    2. One or more blood cytopenias related to CVID (and not due to other medical conditions such as iron-deficiency or lead exposure) defined as hemoglobin <10 g/dL, platelet count <100,000/µL, and/or neutrophil count <1,000/µL
    3. Previous pathologic confirmation of ILD and attributed to CVID by the Investigator with quantifiable CT chest imaging findings evident on baseline CT scan
    4. Clinical diagnosis of CVID enteropathy or other GI tract diagnosis attributable to CVID by the Investigator which involves the small intestine and meets the following enteropathy criteria:

    i. Clinical symptoms of GI disease including at least 1 of: abdominal pain or diarrhea at least 3 days of the week for at least 4 weeks or longer, or dependence on supplemental enteral or parenteral nutrition ii. Lacks a clinical diagnosis of Celiac Disease, and negative human leukocyte antigen (HLA)-DQ2 and -DQ8 testing at screening iii. Presence of small bowel villous shortening/atrophy/blunting with or without intraepithelial lymphocytosis noted in a pathology report pertaining to a small bowel biopsy performed within 5 years of enrollment iv. Negative stool PCR Gastrointestinal Profile at screening

  7. At screening, vital signs. Ranges:

    Systolic blood pressure 80-159 mm Hg Diastolic blood pressure 50-109 mm Hg Pulse rate 50-110 beats per minute (bpm) Oxygen saturation 93-100%

  8. Subjects or their legal representatives (for subjects under the age of 18 years) must be able to communicate with the Investigator and understand and comply with the requirements of the study, including an ability to provide written informed consent.

Exclusion Criteria:

  1. Laboratory evidence of significant T cell deficiency including CD4+ T cells <200/uL.

  2. Laboratory evidence of significant NK cell deficiency including NK cells <1% of peripheral blood lymphocytes or less than 50/mcL.

  3. Clinical history of infections suggestive of clinically significant T cell or NK cell deficiency such as Pneumocystis jirovecii, atypical mycobacteria, severe warts, or unusually severe (as determined by the PI) infections with herpesviruses.

  4. Presence of uncontrolled chronic/recurrent infectious disease (except those considered to be characteristic of antibody deficiency).

  5. Positive blood polymerase chain reaction (PCR) for cytomegalovirus.

  6. Evidence of tuberculosis infection

  7. Positive blood cryptococcal antigen

  8. Previous or concurrent use of immunosuppressive medication, such as:

    • Use of an mTOR inhibitor or a PI3K inhibitor within 3 weeks.
    • Rituximab or other B cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months.
    • Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other Janus kinase (JAK) inhibitors within 3 weeks.
    • Glucocorticoids above 25 mg prednisone or equivalent per day within 2 weeks
    • Immunosuppressive monoclonal or polyclonal antibody therapeutics such as directed against TNF-alpha, α₄β₇ integrin, IL-6, IL-12/IL-23 and others within 5 half-lives
    • Other immunosuppressive agents expected to have a significant impact on immune cell number or function.
    • Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months .
    • Enteral budesonide is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months.
  9. Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer).

  10. HIstory of hypersensitivity to the study drug or to drugs of similar chemical classes.

  11. Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme cytochrome P450 CYP3A.

  12. Current use of medications that, to a larger extent, are BCRP, OATP1B1, and/or OATP1B3 substrates.

  13. History of HIV or positive test result at screening.

  14. Any surgical or medical condition which may jeopardize the subject in case of participation in the study.

    • Chronic need for supplemental oxygen or invasive or non-invasive respiratory support.
    • Liver failure or clinically significant liver disease or dysfunction as indicated by alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2.5 times the upper limit of normal, bilirubin greater than 1.5 times the upper limit of normal, international normalized ratio (INR) greater than 1.5 in the absence of anticoagulation, or presence of diuretic refractory ascites.
    • Elevation of ALT or AST up to 6 times the upper limit of normal is allowed if elevation is determined to be a consequence of immune dysregulation by the site Principal Investigator and if the elevation has been stable for 3 months prior to enrollment.
    • History of significant renal injury/renal disease severely affecting renal function or presence of impaired renal function as indicated by estimated glomerular filtration rate of less than 30 mL/min/1.73 m2.
  15. A positive hepatitis B surface antigen (HBsAg), positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening.

  16. Administration of live vaccines starting from 6 weeks before first dose of study medication

  17. Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication or has evidence of residual disease from a previously diagnosed malignancy, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.

  18. Subject has a previous diagnosis of lymphoma that has been treated with chemotherapy, radiotherapy, or transplant within 1 year of the first dose of study medication or is anticipated to require lymphoma treatment within 6 months of the first dose of study medication.

  19. Subject has uncontrolled post-transplant lymphoproliferative disease-like Epstein-Barr virus related lymphoproliferative disease.

  20. Donation or loss of 400mL or more of blood within 8 weeks before the first dose of study medication

  21. Subject has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first dose of study medication or has a planned or expected major surgical procedure during the study period.

  22. Pregnant or nursing (lactating) women.

  23. Individuals of child-bearing potential, unless they are using highly effective methods of contraception

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Leniolisib

All subjects participating will receive leniolisib film-coated tablets (FCTs) with a planned dose regimen consisting of a starting dose of 10 mg twice daily (BID) for 4 weeks, followed by a dose escalation to 30 mg BID for 4 weeks, and then 70 mg BID for an additional 16 weeks.

Planned dose will range from 10 mg twice daily to 70 mg twice daily

Altri nomi:
  • Joenja

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety & Tolerability
Lasso di tempo: From baseline to the end of 24 weeks of treatment

To assess the number of AEs/SAEs and number of participants with AEs/SAEs

From baseline to the end of 24 weeks of treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Impact of leniolisib on lymphoproliferation measured as index lesions
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Percent change from baseline in lymphadenopathy measured as the sum of product of diameters (SPD) in the index lesions selected per the Cheson methodology

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on lymphoproliferation measured as non-index lesions
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Percent change from baseline in lymphadenopathy measured as SPD of measurable non-index lesions selected as per the Cheson methodology

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on spleen size
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Percent change from baseline in splenomegaly measured by three-dimensional (3D) volume and bi-dimensional (2D) size of spleen

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on hemoglobin
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Hemoglobin will be evaluated over time

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on platelets
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Platelet count will be evaluated over time

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on neutrophils
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Absolute neutrophil counts will be evaluated over time

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on GLILD or other PID-related ILD
Lasso di tempo: From baseline to the end of 24 weeks of treatment

The change in CT evidence of GLILD or other PID-related ILD over time will be compared using the Hartmann Scoring Methodology

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on pulmonary function in FEV1
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Change in FEV1 will be evaluated

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on pulmonary function in FVC
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Change in FVC will be evaluated

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on pulmonary function in TLC
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Change in TLC will be evaluated

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on pulmonary function in DLCO
Lasso di tempo: From baseline to the end of 24 weeks of treatment

Change in DLCO will be evaluated

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on B and T cell subsets of interest
Lasso di tempo: From baseline to the end of 24 weeks of treatment

The percentages of naïve B cells, CD21low B cells, and T regulatory cells over time

From baseline to the end of 24 weeks of treatment
Impact of leniolisib on CXCL13 and soluble IL-2Rα levels
Lasso di tempo: From baseline to the end of 24 weeks of treatment

The levels of CXCL13 and soluble IL-2Rα over time

From baseline to the end of 24 weeks of treatment
To assess the PK of leniolisib in CVID (Cmax)
Lasso di tempo: From baseline to the end of 24 weeks of treatment

PK parameters for leniolisib defined by Cmax

From baseline to the end of 24 weeks of treatment
To assess the PK of leniolisib in CVID (AUC0-t)
Lasso di tempo: From baseline to the end of 24 weeks of treatment

PK parameters for leniolisib defined by AUC0-t

From baseline to the end of 24 weeks of treatment
To assess the PK of leniolisib in CVID (Tmax)
Lasso di tempo: From baseline to the end of 24 weeks of treatment

PK parameters for leniolisib defined by Tmax

From baseline to the end of 24 weeks of treatment
To assess the PK of leniolisib in CVID (T½)
Lasso di tempo: From baseline to the end of 24 weeks of treatment

PK parameters for leniolisib defined by T½

From baseline to the end of 24 weeks of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 febbraio 2025

Completamento primario (Effettivo)

12 agosto 2026

Completamento dello studio (Effettivo)

12 agosto 2026

Date di iscrizione allo studio

Primo inviato

12 marzo 2025

Primo inviato che soddisfa i criteri di controllo qualità

20 marzo 2025

Primo Inserito (Effettivo)

26 marzo 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • LE 8201

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi